| Literature DB >> 35475787 |
Ryan A Mace1, Jonathan Greenberg1, Nicole Lemaster2, Brooke Duarte3, Terence Penn1, Millan Kanaya3, James D Doorley1, Jessica L Burris4, Cale A Jacobs2, Ana-Maria Vranceanu1.
Abstract
BACKGROUND: Knee osteoarthritis (KOA) is the most common joint disorder in the United States and a leading cause of disability. Depression and obesity are highly comorbid with KOA and accelerate knee degeneration and disability through biopsychosocial mechanisms. Mind-body physical activity programs can engage biological, mechanical, and psychological mechanisms to improve outcomes in KOA, but such programs are not currently available.Entities:
Keywords: depression; knee osteoarthritis; mind-body; mixed-methods; mobile phone; obesity; physical activity
Year: 2022 PMID: 35475787 PMCID: PMC9096632 DOI: 10.2196/34654
Source DB: PubMed Journal: JMIR Form Res ISSN: 2561-326X
Figure 1Participant flow for the focus groups (phase 1). PHQ-9: 9-item Patient Health Questionnaire.
GetActive-OA session overview informed by the focus group results.
| Topic | GetActive-OA skills |
| 1. Break the disability spiral by exercising | Myths about pain, disability spiral, and quota-based pacing |
| 2. Smart ways to exercise more | Exercising with enjoyment, self-compassion and gratitude, and diaphragmatic breathing |
| 3. Mindfulness | Mindfulness, mindful breathing, body scan, and mindful moments |
| 4. Everyday mindfulness | Leaning into difficulty, mindfulness of pain, mindful exercising, and noticing the benefits of exercising |
| 5. The benefits and barriers to exercise | Mindful eating, overcoming barriers to exercising, stop and breathe, reflect, and choose |
| 6. Coping with negative thoughts | Negative automatic thoughts, changing our perspective, and acceptance |
| 7. Strengthening social support | Social support and the disability cycle, effective communication, social walking, and loving kindness |
| 8. Staying on track and maintaining your progress | The powerful self; working with pain, your emotional well-being, and unhealthy weight; and resiliency plan |
Figure 2Participant flow for the live video open pilot study (phase 2). OA: osteoarthritis.
Demographics and clinical characteristics of open pilot study participants (N=5).
| Characteristics | Value | ||
| Age (years), mean (SD; range) | 53.2 (6.64; 49-65) | ||
| BMI (kg/m2), mean (SD; range) | 39.8 (6.68; 32.6-50.8) | ||
|
| |||
|
| Male | 0 (0) | |
|
| Female | 5 (100) | |
|
| |||
|
| Hispanic or Latinx | 1 (20) | |
|
| Not Hispanic or Latinx | 4 (80) | |
|
| |||
|
| White | 4 (80) | |
|
| African American | 1 (20) | |
|
| |||
|
| Single, never married | 1 (20) | |
|
| Widowed | 1 (20) | |
|
| Married | 3 (60) | |
|
| |||
|
| Completed high school or GEDa | 2 (40) | |
|
| Associate’s degree | 2 (40) | |
|
| Some college | 1 (20) | |
|
| |||
|
| Employed full-time | 3 (60) | |
|
| Homemaker | 1 (20) | |
|
| On disability | 1 (20) | |
|
| |||
|
| Bilateral | 3 (60) | |
|
| Unilateral | 2 (40) | |
|
| |||
|
| Yes | 3 (60) | |
|
| No | 2 (40) | |
|
| |||
|
| Yes | 1 (20) | |
|
| No | 4 (80) | |
aGED: graduate equivalency degree.
bOA: osteoarthritis.
A priori feasibility markers.
| Marker | Criteria |
| Feasibility of recruitment | Of 10 eligible patients, 6 (60%) successfully contacted agreed to participate (poor) |
| Program acceptability | Of 5 participants, 4 (80%) attended ≥63% (≥5/8) of group or make-up sessions (good) |
| Credibility and expectancy | Of 5 participants, 5 (100%) scored above the scale midpoint for expectancy (good), and 5 (100%) scored above the scale midpoint for credibility (good) |
| Study clinician adherence | The study clinicians delivered 90% of the manual content across the 8 sessions (good) |
| Feasibility of quantitative measures | Of 5 participants, 5 (100%) were not fully missing questionnaires on quantitative measures at baseline (good), and 5 (100%) were not fully missing questionnaires on quantitative measures at the postintervention time point (good) |
| Adherence to homework | Of 5 participants, 4 (80%) completed mind-body and walking skills at least four of seven days or one of these skills at least five of seven days (good) |
| Adherence to ActiGraph | Of 5 participants, 4 (80%) who received ActiGraph at baseline wore it for ≥5 of 7 days (good), and 1 (20%) who received ActiGraph at the postintervention time point wore it for 5 of 7 days (poor) |
| Client satisfaction | Of 5 participants, 5 (100%) scored above the scale midpoint (good) |
| Program safety and adverse events | 0 adverse events |
Quantitative outcomes.
| Measure | Baseline, mean (SD) | Postintervention, mean (SD) | Mean difference from the paired sample | Cohen | |
| KOOSa pain | 33.6 (5.5) | 38.0 (14.9) | 4.4 | .36 | 0.39 |
| KOOS symptoms | 32 (16.8) | 39.4 (22.8) | 7.4 | .18 | 0.36 |
| KOOS ADLb | 34.4 (6.7) | 39.6 (14.8) | 5.2 | .54 | 0.45 |
| KOOS QOLc | 14 (6.8) | 14 (15.7) | 0 | .99 | 0 |
| NRSd pain | 7.0 (1.5) | 7.2 (1.4) | 0.2 | .82 | 0.13 |
| PASIPDe | 36 (19.3) | 37.6 (33.8) | 1.6 | .93 | 0.05 |
| PROMISf Depression | 60.6 (7.5) | 52.6 (10.4) | −8.0 | .08 | 0.88 |
| PROMIS Anxiety | 60.8 (9.0) | 52.6 (11.7) | −8.2 | .11 | 0.78 |
| PCSg | 39 (12.5) | 24.4 (10.9) | −14.6 | .10 | 1.24 |
| ASESh | 3.8 (0.8) | 4.8 (1.7) | 1.0 | .30 | 0.73 |
| MOCS-Ai | 22.8 (3.7) | 33 (4.7) | 10.2 | .004 | 2.41 |
| Step countj | 8763 (3813.9) | 7887 (3131.9) | −766 | .37 | 0.22 |
| IL-6k | 3.10 (0.48) | 1.97 (1.75) | −1.13 | .38 | 0.87 |
| TLR4l | 24.27 (33.49) | 16.58 (10.12) | −7.69 | .74 | 0.34 |
| CTX-IIm | 391.1 (153.1) | 629.2 (404.3) | 238.1 | .25 | 0.76 |
aKOOS: Knee Injury and Osteoarthritis Outcome Score.
bADL: activity of daily living.
cQOL: quality of life.
dNRS: Numerical Rating Scale.
ePASIPD: Physical Activity Scale for Persons With Physical Disability.
fPROMIS: Patient-Reported Outcomes Measurement Information System.
gPCS: Pain Catastrophizing Scale.
hASES: Arthritis Self-Efficacy Scale.
iMOCS-A: Measures of Current Status–Part A.
jActiGraph step count, which is the weekly average of the valid days (≥10 hours).
kIL-6: interleukin-6.
lTLR4: Toll-like receptor 4.
mCTX-II: Urine Cartilaps (Immunodiangostic Systems Inc).